
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is a clinical stage biopharmaceutical company focused on developing once-daily tablets for the treatment of ADHD and anxiety, with a potential approval for its novel drugs in late 2026 and commercialization in early 2027. The company's partnership with Prasco, sufficient cash to support operations, and extended IP runway are positive long-term indicators. However, there are risks such as balance sheet and liquidity concerns, competition, and regulatory approval uncertainties that could impact the company's future success. Despite these risks, Ascendiant Capital Markets, LLC has a Buy rating for Cingulate with a 12-month price target of $9 per share.
Bears say
Cingulate is a clinical-stage biopharmaceutical company that focuses on the development of products for the treatment of ADHD and other therapeutic areas using their proprietary drug delivery platform technology. Despite reporting a net loss of $5.9M for the three months ending June 30, 2026, with a cash runway until mid-2027, our DCF models yielded an equity value of $168M and a price target of $9 per share, assuming 18.02M shares outstanding at the end of 2Q27. However, there are risks that could impede shares from achieving our price target, such as regulatory setbacks, slower market penetration of their lead candidate, and potential dilution risk. Additionally, the constantly changing global drug pricing and reimbursement environment could have major ramifications for the company.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares